Celularity Inc.

NASDAQ:CELU

Biotechnology

Healthcare
$1.83 +138.53%

+$1.22 today

Market cap
$52.97M
Beta
0.54
P/E (TTM)
-0.6
EPS (TTM)
-$3.58
52W Low $0.56High $4.00

Volume 0.00M

Average 0.13M

CELU Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Celularity Inc.NASDAQ: CELU

Operating Margin · Q4 FY2025 · quarter ended Dec 2025

Operating margin narrows to -537.5%

Operating margin was -537.5% in Q4 FY2025, down 486.3 pp from a year earlier. On a trailing-twelve-month basis it was -230.9%, down 160.2 pp year over year. Over 3 fiscal years it narrowed by 88.5 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 1 analysts of -99.0% for the fiscal year ending Dec 2026, up from -230.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-537.5%-293.3 pp QoQ
Last fiscal yearDec 2025
-230.9%-160.2 pp YoY
LTMDec 2025
-230.9%-160.2 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-486.3 pp——
1 year-160.2 pp+131.9 pp+292.0 pp
3 years-88.5 pp——
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-230.9%
Year-over-year change
-160.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How CELU compares with its peers on the latest reported figures

  • CELU's LTM Dec 2025 operating margin of -230.9% is the lowest of the 2 companies compared; the peer median is 27.2%.
  • Over three fiscal years its change of -88.5 pp compares with a peer median of -36963.4 pp.
CELU Competitors Peer median
Operating Margin for CELU and competitors
Company Period LTM level YoY 3-year change
ATNMActinium Pharmaceuticals, Inc.LTM Jun 202627.2% —-36963.4 pp
CELUCelularity Inc.LTM Dec 2025-230.9% -160.2 pp-88.5 pp
PYPDPolyPid Ltd.FY2025— ——
ANVSAnnovis Bio, Inc.FY2025— ——
Peer median (excluding CELU) 27.2%—-36963.4 pp

Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.34M17.98M22.77M54.22M26.55M
Cost of Revenue9.65M19.67M16.02M14.99M6.36M
Gross Profit11.68M(1.69M)6.76M39.23M20.19M
Gross Margin54.8%-9.4%29.7%72.4%76.0%
Research & Development88.35M78.36M30.47M17.39M15.03M
Selling, General & Admin71.34M66.02M50.58M58.64M51.27M
Operating Expenses120.74M23.91M199.04M77.59M81.5M
Depreciation & Amortization8.82M9.44M9.32M7.92M7.3M
EBITDA(88.11M)(138.83M)(183.95M)(43.71M)(77.66M)
EBITDA Margin-413.0%-772.4%-807.8%-80.6%-292.5%
Operating Income(109.06M)(25.6M)(192.29M)(38.36M)(61.31M)
Operating Margin-511.2%-142.4%-844.4%-70.7%-230.9%
Interest Income332K365K320K331K262K
Interest Expense3.17M03.02M6.26M6.75M
Other Income / Expenses8.96M39.81M(4M)(19.53M)(30.41M)
Income Before Tax(100.1M)14.21M(196.29M)(57.89M)(91.71M)
Pre-Tax Margin-469.2%79.0%-862.0%-106.8%-345.4%
Income Tax Expense20K13K10K03K
Net Income(100.12M)14.19M(196.3M)(57.89M)(91.8M)
Net Margin-469.3%79.0%-862.0%-106.8%-345.8%
EPS (Basic)(7.87)1.01(11.02)(2.64)(3.59)
EPS (Diluted)(7.87)0.95(11.02)(2.64)(3.59)
Weighted Avg Shares12.73M13.99M17.81M21.89M25.6M
Weighted Avg Shares (Diluted)12.73M14.98M17.81M21.89M25.6M

Celularity Inc.

NASDAQ:CELU

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.